keyword
https://read.qxmd.com/read/38491857/psychiatric-risks-for-worsened-mental-health-after-psychedelic-use
#21
JOURNAL ARTICLE
Alessia Marrocu, Hannes Kettner, Brandon Weiss, Richard J Zeifman, David Erritzoe, Robin L Carhart-Harris
BACKGROUND: Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited by biases and small sample sizes. The current analytical approach was motivated by the question of whether rare but significant adverse effects have been under-sampled in psychedelic research studies...
March 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38486047/structure-activity-relationships-of-serotonergic-5-meo-dmt-derivatives-insights-into-psychoactive-and-thermoregulatory-properties
#22
JOURNAL ARTICLE
Pol Puigseslloses, Núria Nadal-Gratacós, Gabriel Ketsela, Nicola Weiss, Xavier Berzosa, Roger Estrada-Tejedor, Mohammad Nazmul Islam, Marion Holy, Marco Niello, David Pubill, Jordi Camarasa, Elena Escubedo, Harald H Sitte, Raúl López-Arnau
Recent studies have sparked renewed interest in the therapeutic potential of psychedelics for treating depression and other mental health conditions. Simultaneously, the novel psychoactive substances (NPS) phenomenon, with a huge number of NPS emerging constantly, has changed remarkably the illicit drug market, being their scientific evaluation an urgent need. Thus, this study aims to elucidate the impact of amino-terminal modifications to the 5-MeO-DMT molecule on its interactions with serotonin receptors and transporters, as well as its psychoactive and thermoregulatory properties...
March 14, 2024: Molecular Psychiatry
https://read.qxmd.com/read/38485474/uk-medical-students-self-reported-knowledge-and-harm-assessment-of-psychedelics-and-their-application-in-clinical-research-a-cross-sectional-study
#23
JOURNAL ARTICLE
Charlie Song-Smith, Edward Jacobs, James Rucker, Matthew Saint, James Cooke, Marco Schlosser
OBJECTIVE: To capture UK medical students' self-reported knowledge and harm assessment of psychedelics and to explore the factors associated with support for changing the legal status of psychedelics to facilitate further clinical research. DESIGN: Cross-sectional, anonymous online survey of UK medical students using a non-random sampling method. SETTING: UK medical schools recognised by the General Medical Council. PARTICIPANTS: 132 medical students who had spent an average of 3...
March 14, 2024: BMJ Open
https://read.qxmd.com/read/38481684/comparative-pharmacological-effects-of-lisuride-and-lysergic-acid-diethylamide-revisited
#24
JOURNAL ARTICLE
Grant C Glatfelter, Eline Pottie, John S Partilla, Christophe P Stove, Michael H Baumann
Lisuride is a non-psychedelic serotonin (5-HT) 2A receptor (5-HT2A ) agonist and analogue of the psychedelic lysergic acid diethylamide (LSD). Lisuride also acts as an agonist at the serotonin 1A receptor (5-HT1A ), a property known to counter psychedelic effects. Here, we tested whether lisuride lacks psychedelic activity due to a dual mechanism: (1) partial agonism at 5-HT2A and (2) potent agonism at 5-HT1A . The in vitro effects of lisuride, LSD, and related analogues on 5-HT2A signaling were characterized by using miniGαq and β-arrestin 2 recruitment assays...
March 8, 2024: ACS Pharmacology & Translational Science
https://read.qxmd.com/read/38477889/adolescent-psychedelic-use-and-psychotic-or-manic-symptoms
#25
JOURNAL ARTICLE
Otto Simonsson, Miriam A Mosing, Walter Osika, Fredrik Ullén, Henrik Larsson, Yi Lu, Laura W Wesseldijk
IMPORTANCE: While psychedelic-assisted therapy has shown promise in the treatment of certain psychiatric disorders, little is known about the potential risk of psychotic or manic symptoms following naturalistic psychedelic use, especially among adolescents. OBJECTIVE: To investigate associations between naturalistic psychedelic use and self-reported psychotic or manic symptoms in adolescents using a genetically informative design. DESIGN, SETTING, AND PARTICIPANTS: This study included a large sample of adolescent twins (assessed at age 15, 18, and 24 years) born between July 1992 and December 2005 from the Swedish Twin Registry and cross-sectionally evaluated the associations between past psychedelic use and psychotic or manic symptoms at age 15 years...
March 13, 2024: JAMA Psychiatry
https://read.qxmd.com/read/38474476/exploring-novel-antidepressants-targeting-g-protein-coupled-receptors-and-key-membrane-receptors-based-on-molecular-structures
#26
REVIEW
Hanbo Yao, Xiaodong Wang, Jiaxin Chi, Haorong Chen, Yilin Liu, Jiayi Yang, Jiaqi Yu, Yongdui Ruan, Xufu Xiang, Jiang Pi, Jun-Fa Xu
Major Depressive Disorder (MDD) is a complex mental disorder that involves alterations in signal transmission across multiple scales and structural abnormalities. The development of effective antidepressants (ADs) has been hindered by the dominance of monoamine hypothesis, resulting in slow progress. Traditional ADs have undesirable traits like delayed onset of action, limited efficacy, and severe side effects. Recently, two categories of fast-acting antidepressant compounds have surfaced, dissociative anesthetics S-ketamine and its metabolites, as well as psychedelics such as lysergic acid diethylamide (LSD)...
February 22, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38467891/noribogaine-acute-administration-in-rats-promotes-wakefulness-and-suppresses-rem-sleep
#27
JOURNAL ARTICLE
Juan Pedro Castro-Nin, Diego Serantes, Paola Rodriguez, Bruno Gonzalez, Ignacio Carrera, Pablo Torterolo, Joaquín González
Ibogaine is a potent atypical psychedelic that has gained considerable attention due to its antiaddictive and antidepressant properties in preclinical and clinical studies. Previous research from our group showed that ibogaine suppresses sleep and produces an altered wakefulness state, which resembles natural REM sleep. However, after systemic administration, ibogaine is rapidly metabolized to noribogaine, which also shows antiaddictive effects but with a distinct pharmacological profile, making this drug a promising therapeutic candidate...
March 12, 2024: Psychopharmacology
https://read.qxmd.com/read/38464275/brain-substates-induced-by-dmt-relate-to-sympathetic-output-and-meaningfulness-of-the-experience
#28
Lorenzo Pasquini, Alexander Simon, Courtney Gallen, Hannes Kettner, Leor Roseman, Adam Gazzaley, Robin Carhart-Harris, Christopher Timmermann
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic, known to rapidly induce short-lasting alterations in conscious experience, characterized by a profound and immersive sense of physical transcendence alongside rich and vivid auditory distortions and visual imagery. Multimodal neuroimaging data paired with dynamic analysis techniques offer a valuable approach for identifying unique signatures of brain activity - and linked autonomic physiology - naturally unfolding during the altered state of consciousness induced by DMT...
February 19, 2024: bioRxiv
https://read.qxmd.com/read/38455520/psychedelic-substitution-altered-substance-use-patterns-following-psychedelic-use-in-a-global-survey
#29
JOURNAL ARTICLE
Nicolas G Glynos, Jacob S Aday, Daniel Kruger, Kevin F Boehnke, Stephanie Lake, Philippe Lucas
INTRODUCTION: Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date have been limited by small sample sizes and neglecting to include non-North American and European populations. METHODS: We conducted a global, cross-sectional online survey of adults (n = 5,268, 47.2% women) self-reporting past or current psychedelic use and investigated whether psychedelic use was associated with changes in use of other substances...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38451885/diminished-psychedelic-returns-on-distress-marital-status-and-household-size
#30
JOURNAL ARTICLE
Sean M Viña
Although the use of psychedelics to impact health has seen growth, little research has tested the effects of culture conditions on the relationship. More specifically, how does marital status and family size affect the relationship between psychedelics and health? This study tests the relationship between Lifetime Classic Psychedelic Use (LCPU), marital status, and household size (number of people living in a household) on levels of psychological distress in the past 30 days. This project uses pooled data from the National Survey of Drug Use and Health (NSDUH) (2010 to 2018) (N = 674,521)...
2024: PloS One
https://read.qxmd.com/read/38437005/the-relationship-between-changes-in-mindfulness-and-subsequent-changes-in-well-being-following-psychedelic-use-prospective-cohort-study
#31
JOURNAL ARTICLE
Grant Jones, Felipe Herrmann, Adam Bear, Robin Carhart-Harris, Hannes Kettner
This study demonstrates that changes in mindfulness predict subsequent changes in well-being in a data set including individuals who recently engaged in psychedelic use.
March 4, 2024: JMIR Formative Research
https://read.qxmd.com/read/38435972/corrigendum-safety-feasibility-tolerability-and-clinical-effects-of-repeated-psilocybin-dosing-combined-with-non-directive-support-in-the-treatment-of-obsessive-compulsive-disorder-protocol-for-a-randomized-waitlist-controlled-trial-with-blinded-ratings
#32
Terence H W Ching, Lucia Amoroso, Calvin Bohner, Elizabeth D'Amico, Jeffrey Eilbott, Tara Entezar, Madison Fitzpatrick, Geena Fram, Rachael Grazioplene, Jamila Hokanson, Anastasia Jankovsky, Stephen A Kichuk, Bradford Martins, Prerana Patel, Henry Schaer, Sarah Shnayder, Chelsea Witherow, Christopher Pittenger, Benjamin Kelmendi
[This corrects the article DOI: 10.3389/fpsyt.2023.1278823.].
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38433044/trkb-transmembrane-domain-bridging-structural-understanding-with-therapeutic-strategy
#33
REVIEW
Giray Enkavi, Mykhailo Girych, Rafael Moliner, Ilpo Vattulainen, Eero Castrén
TrkB (neuronal receptor tyrosine kinase-2, NTRK2) is the receptor for brain-derived neurotrophic factor (BDNF) and is a critical regulator of activity-dependent neuronal plasticity. The past few years have witnessed an increasing understanding of the structure and function of TrkB, including its transmembrane domain (TMD). TrkB interacts with membrane cholesterol, which bidirectionally regulates TrkB signaling. Additionally, TrkB has recently been recognized as a binding target of antidepressant drugs. A variety of different antidepressants, including typical and rapid-acting antidepressants, as well as psychedelic compounds, act as allosteric potentiators of BDNF signaling through TrkB...
March 2, 2024: Trends in Biochemical Sciences
https://read.qxmd.com/read/38426002/efficacy-and-acceptability-of-psilocybin-for-primary-or-secondary-depression-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#34
Shuping Fang, Xin Yang, Wei Zhang
INTRODUCTION: Psilocybin is a classic psychedelics, which has been shown to have antidepressant effects by many studies in recent years. In this study, we aim to evaluate the efficacy, acceptability and tolerability of psilocybin in the treatment of primary (major depressive disorder) or secondary (experiencing distress related to life-threatening diagnoses and terminal illness) depression. METHODS: We searched PubMed, EMBASE, Web of Science, Cochrane Library and ClinicalTrials...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38423367/predicting-the-outcome-of-psilocybin-treatment-for-depression-from-baseline-fmri-functional-connectivity
#35
JOURNAL ARTICLE
Débora Copa, David Erritzoe, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, Enzo Tagliazucchi
BACKGROUND: Psilocybin is a serotonergic psychedelic drug under assessment as a potential therapy for treatment-resistant and major depression. Heterogeneous treatment responses raise interest in predicting the outcome from baseline data. METHODS: A machine learning pipeline was implemented to investigate baseline resting-state functional connectivity measured with functional magnetic resonance imaging (fMRI) as a predictor of symptom severity in psilocybin monotherapy for treatment-resistant depression (16 patients administered two 5 mg capsules followed by 25 mg, separated by one week)...
February 27, 2024: Journal of Affective Disorders
https://read.qxmd.com/read/38423256/exposure-to-the-psychedelic-substance-25h-nbome-disrupts-maternal-care-in-lactating-rats-and-subsequently-impairs-the-social-play-behavior-of-the-offspring
#36
JOURNAL ARTICLE
Lídia M Melo, Wellington A de Barros, Ângelo de Fátima, Fabiana C Vilela Giusti, Alexandre Giusti-Paiva
Given the critical role of maternal care in the neurodevelopment of offspring, this study aimed to investigate the effects of the psychedelic substance 25H-NBOMe on maternal behavior in lactating rats and its subsequent impact on the social and neurodevelopmental behavior of the offspring. We administered two different dosages of 25H-NBOMe (0.3mg/kg and 1.0mg/kg; i,p,) to lactating rats and observed changes in maternal behaviors, such as nest-building and pup retrieval, and in offspring behaviors, including social play...
February 27, 2024: Behavioural Brain Research
https://read.qxmd.com/read/38421388/psychedelic-assisted-therapy-for-people-with-gambling-disorder
#37
REVIEW
Pedro Romero, Andrea Czakó, Wim van den Brink, Zsolt Demetrovics
Gambling disorder is a severe mental health and behavioural problem with harmful consequences, including financial, relationship and mental health problems. The present paper initiates discussion on the use of psychedelics combined with psychotherapeutic support as a potential treatment option for people living with a gambling disorder. Recent studies have shown promising results using psychedelic-assisted therapy (PAT) to treat anxiety, depression, post-traumatic stress disorder, and various substance use disorders...
February 28, 2024: Journal of Behavioral Addictions
https://read.qxmd.com/read/38420171/flicker-light-stimulation-enhances-the-emotional-response-to-music-a-comparison-study-to-the-effects-of-psychedelics
#38
JOURNAL ARTICLE
Caspar Montgomery, Ioanna Alicia Amaya, Timo Torsten Schmidt
Flicker light stimulation (FLS) is a non-pharmacological method of inducing altered states of consciousness (ASCs), producing hallucination-like phenomena as well as effects extending beyond the visual modality, including emotional effects. Research into the psychological and neural mechanisms of FLS is still in its infancy, but can be informed by research into other methods of inducing ASCs. For instance, research on classic psychedelics has reported enhancement of emotional responses to music. Here, we test to what degree FLS might also enhance the emotional response to music, using a study protocol designed to resemble a previous study on the effects of LSD as closely as possible, to allow for comparison of effect sizes across modalities and inform future research into FLS as an ASC-induction method...
2024: Frontiers in Psychology
https://read.qxmd.com/read/38419183/the-origin-of-2-5-dimethoxy-4-methylamphetamine-dom-stp
#39
JOURNAL ARTICLE
Keeper Trout, Paul F Daley
The story of the 1967 appearance of the powerful psychedelic 2,5-dimethoxy-4-methylamphetamine (DOM, STP) commonly omits details and often includes hyperbole and inaccuracies. It is well known how and when the drug was first distributed to the public for free by Owsley Stanley, but the role that Alexander Shulgin played in providing that material is not as well understood. In the interest of transparency and historical accuracy, this article attempts to present an accurate account of this well-known but inadequately detailed event...
February 28, 2024: Drug Testing and Analysis
https://read.qxmd.com/read/38415202/erratum-to-history-repeating-guidelines-to-address-common-problems-in-psychedelic-science
#40
(no author information available yet)
[This corrects the article DOI: 10.1177/20451253231198466.].
2024: Therapeutic Advances in Psychopharmacology
keyword
keyword
12941
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.